Table 1.

Relative proliferation rate of bladder cancer cell lines treated with PPARG modulators.

Cell Line	Pathway Alteration	GW9662	SR2595	T0070907	SR10221
HT-1197	RXRA p.S427F	127	78	48**	64*
5637	PPARG amplified	93	117	51**	73**
UM-UC-9	PPARG amplified	108	97	19**	20**
RT112/84	PPARG signature	98	101	69**	80**
UM-UC-1	PPARG signature	96	84	47**	62**
Cal29	PPARG signature	97	86	55**	74*
SW1710	Not altered	99	91	96	81
KU19.19	Not altered	85	91	95	91
UM-UC-3	Not altered	92	102	91	96

Relative proliferation rate of bladder cancer cell lines treated with PPARG inhibitors at 100nM compared to DMSO vehicle, reported as percent of vehicle control (POC), in long-term kinetic proliferation assays. Percent of DMSO control was calculated by determining the relative number of cells for treatment versus DMSO control at the timepoint where DMSO control reached 50% confluence (see Fig. 4B for graphical representation) by counting fluorescently labeled nuclei (IncuCyte Zoom). Significant differences in cell number for test sample relative to DMSO control were calculated using two-way ANOVA with Dunnett’s multiple comparison test(*P<0.01, **P <0.001).